HYBRiD XL®

BioCheck, Inc.

United States

BioCheck, founded in 1997, has nearly three decades of experience in the development and production of high quality immunodiagnostic reagents and assays solutions. Headquartered in Pleasant Hill, California, the company has strengthened its scientific and manufacturing capabilities, building a solid presence in both the research and diagnostic markets. BioCheck's products are trusted by diagnostic manufacturers, research laboratories, and healthcare organizations that rely on accuracy, consistency, and reproducibility. In 2021, BioCheck acquired DRG, a well-established and high-quality immunoassay company with operations in the United States, Germany, Russia, Poland and Czech Republic and extensive global distributor partners around the world. As part of its strategic growth, BioCheck has significantly expanded its manufacturing footprint to support its sister company, DRG. This includes the production of ELISA and CLIA assays, enabling the organization to deliver a broader portfolio of immunoassay solutions to global partners and customers. The combined capabilities of BioCheck and DRG strengthen the company's position as a comprehensive provider of diagnostic reagents and assay systems. Whether supporting a global diagnostic manufacturer or a research laboratory, BioCheck provides the expertise, flexibility, and consistency required to advance scientific discovery and improve patient outcomes.